Beranda › Leukemia Mieloid Akut › Missouri
Uji klinis Leukemia Mieloid Akut di Missouri
23 studi untuk Leukemia Mieloid Akut mencari peserta di lokasi di Missouri.
Kota di Missouri
Teks studi resmi (Bahasa Inggris)
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- Washington University /ID# 280295, St Louis
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07581002Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- dan 21 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- dan 2 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06484062Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- dan 2 lainnya
Menerima pesertaFase 2
Usia 18 hingga 59 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Washington University in St Louis, St Louis
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Parkland Health Center - Farmington, Farmington
- dan 10 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- dan 2 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- dan 2 lainnya
Menerima pesertaFase 2
Usia 18 hingga 59 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Children's Mercy Hospitals and Clinics, Kansas City
- Washington University School of Medicine, St Louis
- Mercy Hospital Saint Louis, St Louis
Menerima pesertaFase 3
6 Months – 21 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Washington University in St. Louis School of Medicine, St Louis
Menerima pesertaFase 1/2
30 Days · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT04065399A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Washington University in St. Louis, St Louis
Menerima pesertaStudi observasional
Usia 0 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07154823Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-St Louis MO-WASHU, St Louis
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT07223814Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
- Washington University in St Louis, St Louis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT06533761The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Missouri Children's Hospital, Columbia
- Children's Mercy Hospitals and Clinics, Kansas City
- Cardinal Glennon Children's Medical Center, St Louis
- dan 2 lainnya
Menerima pesertaFase 1/2
Hingga usia 22 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04726241Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
- Washington University School of Medicine, St Louis
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT06158828Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- The Children's Mercy Hospital - Adele Hall Campus, Kansas City
- Washington University School of Medicine in St. Louis, St Louis
Menerima pesertaFase 3
29 Days – 21 Years · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT05183035Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Washington University School of Medicine, St Louis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT06001788Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
- Washington University, St Louis
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT06529731Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Children's Mercy Hospital of Kansas City, Kansas City
Menerima pesertaFase 1
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06177067Motixafortide for MRD Sensitization in AML
- Washington University School of Medicine, St Louis
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT07392970A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Children's Mercy Hospital and Clinics, Kansas City
- Cardinal Glennon Children's Medical Center, St Louis
- Washington University St. Louis, St Louis
- dan 1 lainnya
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT01351545A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Washington University in St. Louis, St Louis
Menerima pesertaFase 1
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 16 Mar 2026 · NCT06994676Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
- Washington University School of Medicine, St Louis
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Okt 2025 · NCT04986657Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.